Recent News

• 05.14.2026 - Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
• 05.07.2026 - Profound Medical Reports Strong First Quarter 2026 Financial Results
• 04.16.2026 - Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
• 04.14.2026 - Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
• 04.01.2026 - Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
• 03.27.2026 - Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
• 03.13.2026 - CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

Recent Filings

• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2026 - EX-99.1 EX-99.1
• 05.07.2026 - 8-K Current report
• 04.16.2026 - EX-99.1 EX-99.1
• 04.16.2026 - 8-K Current report
• 04.14.2026 - 8-K Current report
• 04.14.2026 - EX-99.1 EX-99.1
• 04.01.2026 - 8-K Current report
• 04.01.2026 - EX-99.1 EX-99.1
• 03.27.2026 - EX-99.1 EX-99.1